Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00387517
Status:
COMPLETED
Last Update Posted:
2017-02-07
First Post:
2006-10-11
Brief Title:
SafetyEfficacy of Combo Therapy With Aliskiren Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren HCTZ 15025 mg and 30025 mg in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskirenhydrochlorothiazide HCTZ 15025 mg and 30025 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None